EC approves lebrikizumab for atopic dermatitis
Monoclonal antibody, lebrikizumab, is approved in Europe for treatment of adults and adolescents with moderate-to-severe atopic dermatitis.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
